Literature DB >> 20090097

Newcastle disease virus as an oncolytic agent.

P V Ravindra1, Ashok K Tiwari, Bhaskar Sharma, R S Chauhan.   

Abstract

Cancer is a major cause of deaths in humans. Though there has been significant progress in cancer therapy, the limited efficacy and toxicities of current chemo- and radiotherapies have provided an impetus for the search of new therapeutics. A therapeutic approach, which uses viruses for the treatment of cancer termed, oncolytic virotherapy has recently emerged. Newcastle disease virus (NDV) is one such virus with an inherent oncolytic property. NDV causes a highly infectious disease in poultry worldwide. In humans it is reported to have oncolytic and immuno-stimulatory effects. It specifically replicates in tumour cells while sparing normal cells and cause oncolysis. For many years different strains of the NDV have been investigated for treatment of various human cancers. Recent advances in reverse genetics provided investigators the tools to produce recombinant NDV with improved oncolytic property.

Entities:  

Mesh:

Year:  2009        PMID: 20090097

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  14 in total

1.  Antineoplastic activity of Newcastle disease virus strain D90 in oral squamous cell carcinoma.

Authors:  Chun-Xiao Zhang; Long-Wei Ye; Ying Liu; Xiao-Ya Xu; Dan-Rui Li; Yan-Qing Yang; Lu-Lu Sun; Jie Yuan
Journal:  Tumour Biol       Date:  2015-04-16

2.  Cytolytic replication of echoviruses in colon cancer cell lines.

Authors:  Stina Israelsson; Nina Jonsson; Maria Gullberg; A Michael Lindberg
Journal:  Virol J       Date:  2011-10-14       Impact factor: 4.099

3.  Analysis of codon usage in Newcastle disease virus.

Authors:  Meng Wang; Yong-Sheng Liu; Jian-Hua Zhou; Hao-Tai Chen; Li-Na Ma; Yao-Zhong Ding; Wen-Qian Liu; Yuan-Xing Gu; Jie Zhang
Journal:  Virus Genes       Date:  2011-01-20       Impact factor: 2.332

4.  Loss of stress response as a consequence of viral infection: implications for disease and therapy.

Authors:  Philip L Hooper; Lawrence E Hightower; Paul L Hooper
Journal:  Cell Stress Chaperones       Date:  2012-07-14       Impact factor: 3.667

Review 5.  Oncolytic viruses & their specific targeting to tumour cells.

Authors:  Prafull K Singh; Juwar Doley; G Ravi Kumar; A P Sahoo; Ashok K Tiwari
Journal:  Indian J Med Res       Date:  2012-10       Impact factor: 2.375

Review 6.  Targeting pediatric cancer stem cells with oncolytic virotherapy.

Authors:  Gregory K Friedman; Kevin A Cassady; Elizabeth A Beierle; James M Markert; G Yancey Gillespie
Journal:  Pediatr Res       Date:  2012-02-15       Impact factor: 3.756

7.  Effect of recombinant Newcastle disease virus transfection on lung adenocarcinoma A549 cells in vivo.

Authors:  Yulan Yan; Lijuan Jia; Jin Zhang; Yang Liu; Xuefeng Bu
Journal:  Oncol Lett       Date:  2014-09-25       Impact factor: 2.967

Review 8.  Exploring the Prospects of Engineered Newcastle Disease Virus in Modern Vaccinology.

Authors:  Muhammad Bashir Bello; Khatijah Yusoff; Aini Ideris; Mohd Hair-Bejo; Abdurrahman Hassan Jibril; Ben P H Peeters; Abdul Rahman Omar
Journal:  Viruses       Date:  2020-04-16       Impact factor: 5.048

9.  Differential microRNA Expression in Newcastle Disease Virus-Infected HeLa Cells and Its Role in Regulating Virus Replication.

Authors:  Yu Chen; Shanshan Zhu; Yuru Pei; Jiao Hu; Zenglei Hu; Xiaowen Liu; Xiaoquan Wang; Min Gu; Shunlin Hu; Xiufan Liu
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

10.  Targeting Melanoma with Cancer-Killing Viruses.

Authors:  Tiantian Zhang; Yogesh R Suryawanshi; Helene M Woyczesczyk; Karim Essani
Journal:  Open Virol J       Date:  2017-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.